Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

Lignende værker

• IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association
  af: Debarri, Houria, et al.
  Udgivet: (2015)
• Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial
  af: Renneville, Aline, et al.
  Udgivet: (2014)
• Comprehensive mutational profiling of core binding factor acute myeloid leukemia
  af: Duployez, Nicolas, et al.
  Udgivet: (2016)
• Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia
  af: Peterlin, Pierre, et al.
  Udgivet: (2015)
• Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype
  af: Fenwarth, Laurène, et al.
  Udgivet: (2019)